Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report

Maurie Markman, Karen A. Iseminger, Kenneth D Hatch, William T. Creasman, Willard Barnes M, Brent Dubeshter

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

There is a critical need to find additional effective therapies in the management of ovarian cancer. A previously reported Gynecologic Oncology Group trial demonstrated that tamoxifen is an active drug when used in the salvage setting in this malignancy. Unfortunately, this original report did not specifically examine the utility of tamoxifen in patients with clinically defined platinum-refractory disease. In this reanalysis of the results of treatment of 102 evaluable patients entered into this multi-institutional trial, an objective response rate of 13% (95% confidence interval, 6.422.6%) was observed in patients with cisplatin-refractory ovarian cancer. The median response duration in this patient population was 4.4 months (range 1.2-9.2 months). Although the response rate is modest, this well-tolerated hormonal agent is a reasonable therapeutic option in selected patients with ovarian cancer when salvage therapy is to be considered. A possible role for this hormonal agent in other clinical settings in ovarian cancer will need to be defined through the conduct of carefully designed randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)4-6
Number of pages3
JournalGynecologic Oncology
Volume62
Issue number1
DOIs
StatePublished - Jul 1996

Fingerprint

Tamoxifen
Platinum
Ovarian Neoplasms
Salvage Therapy
Cisplatin
Therapeutics
Randomized Controlled Trials
Confidence Intervals
Pharmaceutical Preparations
Population
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Tamoxifen in platinum-refractory ovarian cancer : A Gynecologic Oncology Group ancillary report. / Markman, Maurie; Iseminger, Karen A.; Hatch, Kenneth D; Creasman, William T.; Barnes M, Willard; Dubeshter, Brent.

In: Gynecologic Oncology, Vol. 62, No. 1, 07.1996, p. 4-6.

Research output: Contribution to journalArticle

Markman, Maurie ; Iseminger, Karen A. ; Hatch, Kenneth D ; Creasman, William T. ; Barnes M, Willard ; Dubeshter, Brent. / Tamoxifen in platinum-refractory ovarian cancer : A Gynecologic Oncology Group ancillary report. In: Gynecologic Oncology. 1996 ; Vol. 62, No. 1. pp. 4-6.
@article{62ca854702dd4b9883ce60fc8158bfe2,
title = "Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report",
abstract = "There is a critical need to find additional effective therapies in the management of ovarian cancer. A previously reported Gynecologic Oncology Group trial demonstrated that tamoxifen is an active drug when used in the salvage setting in this malignancy. Unfortunately, this original report did not specifically examine the utility of tamoxifen in patients with clinically defined platinum-refractory disease. In this reanalysis of the results of treatment of 102 evaluable patients entered into this multi-institutional trial, an objective response rate of 13{\%} (95{\%} confidence interval, 6.422.6{\%}) was observed in patients with cisplatin-refractory ovarian cancer. The median response duration in this patient population was 4.4 months (range 1.2-9.2 months). Although the response rate is modest, this well-tolerated hormonal agent is a reasonable therapeutic option in selected patients with ovarian cancer when salvage therapy is to be considered. A possible role for this hormonal agent in other clinical settings in ovarian cancer will need to be defined through the conduct of carefully designed randomized clinical trials.",
author = "Maurie Markman and Iseminger, {Karen A.} and Hatch, {Kenneth D} and Creasman, {William T.} and {Barnes M}, Willard and Brent Dubeshter",
year = "1996",
month = "7",
doi = "10.1006/gyno.1996.0181",
language = "English (US)",
volume = "62",
pages = "4--6",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Tamoxifen in platinum-refractory ovarian cancer

T2 - A Gynecologic Oncology Group ancillary report

AU - Markman, Maurie

AU - Iseminger, Karen A.

AU - Hatch, Kenneth D

AU - Creasman, William T.

AU - Barnes M, Willard

AU - Dubeshter, Brent

PY - 1996/7

Y1 - 1996/7

N2 - There is a critical need to find additional effective therapies in the management of ovarian cancer. A previously reported Gynecologic Oncology Group trial demonstrated that tamoxifen is an active drug when used in the salvage setting in this malignancy. Unfortunately, this original report did not specifically examine the utility of tamoxifen in patients with clinically defined platinum-refractory disease. In this reanalysis of the results of treatment of 102 evaluable patients entered into this multi-institutional trial, an objective response rate of 13% (95% confidence interval, 6.422.6%) was observed in patients with cisplatin-refractory ovarian cancer. The median response duration in this patient population was 4.4 months (range 1.2-9.2 months). Although the response rate is modest, this well-tolerated hormonal agent is a reasonable therapeutic option in selected patients with ovarian cancer when salvage therapy is to be considered. A possible role for this hormonal agent in other clinical settings in ovarian cancer will need to be defined through the conduct of carefully designed randomized clinical trials.

AB - There is a critical need to find additional effective therapies in the management of ovarian cancer. A previously reported Gynecologic Oncology Group trial demonstrated that tamoxifen is an active drug when used in the salvage setting in this malignancy. Unfortunately, this original report did not specifically examine the utility of tamoxifen in patients with clinically defined platinum-refractory disease. In this reanalysis of the results of treatment of 102 evaluable patients entered into this multi-institutional trial, an objective response rate of 13% (95% confidence interval, 6.422.6%) was observed in patients with cisplatin-refractory ovarian cancer. The median response duration in this patient population was 4.4 months (range 1.2-9.2 months). Although the response rate is modest, this well-tolerated hormonal agent is a reasonable therapeutic option in selected patients with ovarian cancer when salvage therapy is to be considered. A possible role for this hormonal agent in other clinical settings in ovarian cancer will need to be defined through the conduct of carefully designed randomized clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0030201090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030201090&partnerID=8YFLogxK

U2 - 10.1006/gyno.1996.0181

DO - 10.1006/gyno.1996.0181

M3 - Article

C2 - 8690289

AN - SCOPUS:0030201090

VL - 62

SP - 4

EP - 6

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -